0000950170-22-011717.txt : 20220616 0000950170-22-011717.hdr.sgml : 20220616 20220616081920 ACCESSION NUMBER: 0000950170-22-011717 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20220615 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20220616 DATE AS OF CHANGE: 20220616 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SQZ Biotechnologies Co CENTRAL INDEX KEY: 0001604477 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 462431115 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39662 FILM NUMBER: 221019375 BUSINESS ADDRESS: STREET 1: 200 ARSENAL YARDS BLVD., STE. 210 CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 617-898-8824 MAIL ADDRESS: STREET 1: 200 ARSENAL YARDS BLVD., STE. 210 CITY: WATERTOWN STATE: MA ZIP: 02472 8-K 1 sqz-20220615.htm 8-K 8-K
false000160447700016044772022-06-152022-06-15

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 15, 2022

 

 

SQZ BIOTECHNOLOGIES COMPANY

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-39662

46-2431115

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

200 Arsenal Yards Blvd

Suite 210

 

Watertown, Massachusetts

 

02472

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 617 758-8672

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.001 par value per share

 

SQZ

 

The New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

SQZ Biotechnologies Company (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”) on June 15, 2022, at which a quorum was present. As of April 18, 2022, the record date for the Annual Meeting, there were 28,148,125 outstanding shares of the Company’s common stock. The Company’s stockholders voted on the following matters, which are described in detail in the Company’s Definitive Proxy Statement filed with the U.S. Securities and Exchange Commission on April 26, 2022. The voting results for each proposal are also described below.

 

Item 1: To elect Amy W. Schulman, Klavs F. Jensen, Ph.D., Sapna Srivastava, Ph.D., and Bernard Coulie, M.D., Ph.D. as Class II directors to serve until the 2025 annual meeting of stockholders and until their respective successors shall have been duly elected and qualified.

 

Class II Director Nominee

 

For

 

Withheld

 

Broker Non-Votes

Amy W. Schulman

 

16,413,248.84

 

1,612,300.00

 

5,644,678.00

Klavs F. Jensen, Ph.D.

 

15,366,385.84

 

2,659,163.00

 

5,644,678.00

Sapna Srivastava, Ph.D.

 

16,025,867.84

 

1,999,681.00

 

5,644,678.00

Bernard Coulie, M.D., Ph.D.

 

17,771,696.84

 

253,852.00

 

5,644,678.00

 

Item 2: To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022.

 

For

 

Against

 

Abstain

 

Broker Non-Votes

23,669,448.84

 

335.00

 

443.00

 

0.00

 

Based on the foregoing votes, Amy W. Schulman, Klavs F. Jensen, Ph.D., Sapna Srivastava, Ph.D., and Bernard Coulie, M.D., Ph.D. were elected as Class II directors and PricewaterhouseCoopers LLP’s appointment as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022 was ratified.

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

SQZ BIOTECHNOLOGIES COMPANY

 

 

 

 

Date:

June 16, 2022

By:

/s/ Lawrence Knopf

 

 

 

Lawrence Knopf
General Counsel

 

 EX-101.LAB 2 sqz-20220615_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, Address Line Two Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Entity Ex Transition Period Entity File Number Entity Incorporation, State or Country Code Entity Information, Former Legal or Registered Name Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications EX-101.PRE 3 sqz-20220615_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.SCH 4 sqz-20220615.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink XML 5 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Document And Entity Information
Jun. 15, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 15, 2022
Entity Registrant Name SQZ BIOTECHNOLOGIES COMPANY
Entity Central Index Key 0001604477
Entity Emerging Growth Company true
Entity File Number 001-39662
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 46-2431115
Entity Address, Address Line One 200 Arsenal Yards Blvd
Entity Address, Address Line Two Suite 210
Entity Address, City or Town Watertown
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02472
City Area Code 617
Local Phone Number 758-8672
Entity Information, Former Legal or Registered Name N/A
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Ex Transition Period false
Title of 12(b) Security Common Stock, $0.001 par value per share
Trading Symbol SQZ
Security Exchange Name NYSE
XML 6 sqz-20220615_htm.xml IDEA: XBRL DOCUMENT 0001604477 2022-06-15 2022-06-15 false 0001604477 8-K 2022-06-15 SQZ BIOTECHNOLOGIES COMPANY DE 001-39662 46-2431115 200 Arsenal Yards Blvd Suite 210 Watertown MA 02472 617 758-8672 N/A false false false false Common Stock, $0.001 par value per share SQZ NYSE true false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 25 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://sqzbiotech.com/20220615/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports sqz-20220615.htm sqz-20220615.xsd sqz-20220615_lab.xml sqz-20220615_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "sqz-20220615.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "sqz-20220615.htm" ] }, "labelLink": { "local": [ "sqz-20220615_lab.xml" ] }, "presentationLink": { "local": [ "sqz-20220615_pre.xml" ] }, "schema": { "local": [ "sqz-20220615.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 26, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 25, "memberCustom": 0, "memberStandard": 0, "nsprefix": "sqz", "nsuri": "http://sqzbiotech.com/20220615", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "sqz-20220615.htm", "contextRef": "C_a77485f8-5e74-43d4-a37d-8ac37bdd6e08", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document And Entity Information", "role": "http://sqzbiotech.com/20220615/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "sqz-20220615.htm", "contextRef": "C_a77485f8-5e74-43d4-a37d-8ac37bdd6e08", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sqzbiotech.com/20220615/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sqzbiotech.com/20220615/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sqzbiotech.com/20220615/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sqzbiotech.com/20220615/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sqzbiotech.com/20220615/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sqzbiotech.com/20220615/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sqzbiotech.com/20220615/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sqzbiotech.com/20220615/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sqzbiotech.com/20220615/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sqzbiotech.com/20220615/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sqzbiotech.com/20220615/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sqzbiotech.com/20220615/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sqzbiotech.com/20220615/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sqzbiotech.com/20220615/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationFormerLegalOrRegisteredName": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Former Legal or Registered Name of an entity", "label": "Entity Information, Former Legal or Registered Name" } } }, "localname": "EntityInformationFormerLegalOrRegisteredName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sqzbiotech.com/20220615/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sqzbiotech.com/20220615/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sqzbiotech.com/20220615/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sqzbiotech.com/20220615/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sqzbiotech.com/20220615/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sqzbiotech.com/20220615/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sqzbiotech.com/20220615/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sqzbiotech.com/20220615/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sqzbiotech.com/20220615/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sqzbiotech.com/20220615/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sqzbiotech.com/20220615/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 13 0000950170-22-011717-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-22-011717-xbrl.zip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ΟR X9I^&#M.[\SI M=9RV\X?SX;=.I]?I[ RCRRW#LWD$;[UW($;QW(2@(-C"-28N\; ;P$@E?0]# MXK6A'P3P*$:%\(A"Q)Z0WXXU UY!+U!E;$+<"[TY6K@WU)-XYZV=>C83%K0I MF]E.IW-FIZ-*(\0O2X598I?5=:RS;GL3^BW@5X.$,O" G%I0>KU& U0!:(X M;">)97R$(S$@E4GW;Y=\-]I$B/C(EPG3E-3+! 7B]%.F1LX9FL8$(4>0Z4/D MM6?TR?81ML5M(#8LL2%.[J_\Q_!.]/@9(\;QQG@:-OG,!,4S]*^*+14%#I8^K#6_, M%2NHY&'C,%$^R 3UOF!D/^0-K\ MA;:EE/FXFO"N%HC-^.O9%T;7T7Q %TN7E$/JH^M"W8R92T(L7IKBY;F?!@*[X[;:MG.+5HVI#GU*VD C7 M? .Q&S1S@WOVB&8XC!!#_IV[J*KAH.$U%1-GY7=F5 F="ZL);NQNACY?A/ 4 MQQ\F>V[CLGCCN.+#*7B84U(^T0HAQJ$>&)\="_Z.YB'QHC8,PQ5B8_$9PNZG M4RWDWB%U0_\4;JV@(^2M&+_GNLYD+#[]-'B%D-J@KC;>W"4S5#*GM6'FX6B M/?[\([-;OG S[ 8ZM&*0<3#^8!9VT&B[F% =4_:X<9R_^:6)$!%W]HHD"UFH MP=+'9?%$M'!&^);PNQ"QOHZRS@1_#Z4KIGU7S7@%WX-)>FX.\D:$3NM":L"_ M2N6_3_9SEI"B!E><*EODA>J0JN):*%V3E>2LD]-*2,1 J@&7 M,TFN]5-.XU>2$&M"(FJTBH+;*,B77LG1%K M0"QBAE/K:AW)FVA!5JR2N\^RAI[+/)68;^[)G438'N63?AE9,48R?,KH0M># MH]+1,M.MZ.C5 :GMW%&01;^M&4A=/T]Z(O->6S.(E5T^BK7<<&L6>K?W)\^: M6FS-(.[M"%*\U6;;ZX)W#H5W7@M\L7M(BYXSUEX!N+:G2,M>--5> 7Y)IY&V M )V?UF0))?U'67:=@]8D=&574A:]W$)KM(#27J4SJ@L>Y4_UDP19?U2 MBEOKAC6#>F@7E4(_R!E[%:4<7L3KP"_KN%+06ONK651='U8>M^!\-81M6\2^_'Q=OU!X<_Y/@P)9Z+@/))T_@Z M,%N#=K=K?+F]N/G!-,E=I_M('F%!6GY$7^".*I\)-9= /@P>/I)OO_9[I$?Y M7R-/ ;D3_CP$'A&33*-HUK"LQ6)1"\:4*\'F$7:H:KX(+6*:Z_!M"9Y^3NZ\ M"$C#M5W7M*],YW+HNHVZV[#=FOO9_?23;3=L>ZN9F"TEG4PC\L'_2'0K[)MS M8&Q).I1[W*<>(X.TTY])E_LUTF*,]'4K1?J@0+Y 4%O%9*B@P5(9L:(-Y4\A M]'K"3^@UC2T]\4BRFI 3R[7MNK5I58C0O\P49NI'IN.:=:<6J\ @.!M<)7V_ MHI,4'A_@%_4$[5Q?7UO)VPU4T3P@AG6L;P^]0:+3Q!F*<-3 N+T@9#4<4C#H MPYCHSZ_][B:(^ON?$141^--D+O7@VU?.I15YL> B7%JZ@96F0OK9XL$]CVBT M[/*QD&$RJD@QZ6DJ8=PT,*Z9!M-#\V,?XWQ_2YQH.0.,0\,9 \/*E,PDSC:/ M$JS.U35<\SRC*GRLX^]WODL6X@AX $$R[BE?)OP=$--9*.3N<&G>"HDGB:+ MKTW$BQ4 3:CK+\E@)@.)/[ZW!99\:Z0BZ?E1&HEY(V!-X_"]=6XZ+1R]0(]@ MAWF3'#J[[\].IXU3V,*EJ"T"R!N<[==G)Y,FUS-(*C"_ KTVYK#*QY5&;X@1 MC[!*7I^=S*KZ6D& 5:;6'UAEX.0P*\;^9S3=-]!T2Z:ID_Y)#L6"GR*YA2R7 MXK/ 78O]26<%=7L$7"[1 :[_\"2?I7BA>I<]074?7A+9-I:M]%@7-Z3X=U@6 MLMS'E43O/@0YP5/J;U(LHFE;A#./%Y/,1Y=%-1Y*CRNJ-_W5\ES,\Q!:$LD. M9? X#T<@"\EM04HBA0=U(6=")N>EI [:8H[IMCQ:XL=;E49]0/9AX M[$GV84)5!!*"1R\\IN%5S4L2L^H5,S,Z2GH/5A*YH1=W UR$Z)BN[F"%Q?: >3LI)XE5D>(9S0?]$&MJ]0)Q+\F23LDF_ MB6ZI1 ?@SR7FG...AOH&F$/O %(:J?O8GWI\ @4UG0L[/SG!J(_['Y\\X,(M MJB%3.;3R<3OTMDV) MEMREZDD_#8I?=TR20V-JC;!FGL1XIC^E;'/4&4L1YID+:6\B[ZI/A,1:;1J. M;3NV]B9G>"32.=DT\+(T5TA&S#3M_03X/TG:M1,VBIQZ9145>!+99+F5E[;R M,S)%=F45'3%%,GG7[TZ>NR//>1?RMDV8;!UY)ZFY9]]D^JJ[F!QW?3*%U=W; M"JRBK/(^55Q:@/KB]6+_0?_0__-W^"U!+ 0(4 Q0 ( &E"T%29DN\A)A8 !0@ 0 0 M " 0 !S<7HM,C R,C V,34N:'1M4$L! A0#% @ M:4+05 [O(YL/ P FPD ! ( !5!8 '-Q>BTR,#(R,#8Q M-2YX